AVIR Projected Dividend Yield
Atea Pharmaceuticals Inc ( NASDAQ : AVIR )Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Co's existing focus is on the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus. Co.'s product candidate for the treatment of COVID-19 is bemnifosbuvir. For the treatment of chronic HCV infection, Co. is developing a combination of bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A inhibitor. Co. is developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. 20 YEAR PERFORMANCE RESULTS |
AVIR Dividend History Detail AVIR Dividend News AVIR Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |